Allan Camaisa - Dec 17, 2024 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role: CEO and Chairman of the Board, Director
Signature: /s/ Andrew Jackson, Attorney-in-fact
Stock symbol: CLDI
Transactions as of: Dec 17, 2024
Transactions value $: -$16,200
Form type: 4
Date filed: 12/18/2024, 09:29 PM
Previous filing: Sep 30, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLDI	Common Stock	Sale	-$16.2K	-10K	-13.04%	$1.62	66.7K	Dec 17, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected for tax planning purposes. The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request of the SEC staff, the Issuer or a security holder of the Issuer.
F2	Includes 6,557 shares of Common Stock directly held by Allan Camaisa. Does not include (i) 14,000 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2023 Equity Plan, (ii) 6,445 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2019 Equity Plan, (iii) 46,972 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, (iv) 70,760 shares of Common Stock issuable upon exercise of options held by AJC Capital, LLC ("AJC"), (v) 203,954 shares of Common Stock issuable upon exercise of options held by AJC, (vi) 281,513 shares of Common Stock held by AJC, and (vii) 608,383 shares of Common Stock held by Jamir Trust. Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa may be deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust.

Content

The sales reported in this Form 4 were effected for tax planning purposes. The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request of the SEC staff, the Issuer or a security holder of the Issuer.

Includes 6,557 shares of Common Stock directly held by Allan Camaisa. Does not include (i) 14,000 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2023 Equity Plan, (ii) 6,445 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2019 Equity Plan, (iii) 46,972 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, (iv) 70,760 shares of Common Stock issuable upon exercise of options held by AJC Capital, LLC ("AJC"), (v) 203,954 shares of Common Stock issuable upon exercise of options held by AJC, (vi) 281,513 shares of Common Stock held by AJC, and (vii) 608,383 shares of Common Stock held by Jamir Trust. Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa may be deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust.